Kornimate/medical-research-clean huggingface dataset:
serum prolidase activity and the role of leptin in osteomalacia

Conditions: Osteomalacia

Summary: evaluation of the change of serum prolidase and leptin values in the diagnosis and follow-up of osteomalacia and its clinical usability

osteomalacia describes a bone disorder in adults that is usually caused by long-term vitamin d deficiency. osteomalacia, a metabolic bone disease characterized by impaired mineralization of the bone matrix.not a single laboratory finding is specific to osteomalacia.the relationship between collagen and prolidase activity has been observed during fibrotic processes, where an increase in prolidase activity is accompanied by an increase in tissue collagen deposition. it has also been suggested that serum activity is increased in metabolic bone diseases.leptin is a 16 kda peptide hormone. it is a member of the long chain helical cytokine family, which is mainly produced by fat cells and proportional to the size of the stored fat. leptin affects bone remodeling by reducing the activity of osteoclasts and thus participates in the pathogenesis of osteoporosis. in the light of these studies, the investigators planned our study according to the clinical significance of serum prolidase activity in osteomalacia and the place of leptin in osteomalacia.

Eligibility criteria:
inclusion criteria: * among the patients who applied to the outpatient clinic, those with clinical complaints of osteomalacia (diffuse pain, fatigue, rapid fatigue, proximal extremity weakness, etc.) * 25 0h vit. d level of 10ng/ml and below exclusion criteria: * other metabolic and endocrine bone diseases (secondary osteoporosis, paget hast, osteogenesis imperfecta, osteomyelitis etc.) * patients who have previously received treatment for low vitamin d * those with low vitamin d levels due to liver or kidney failure * those who receive treatment for tumor
novel endoscopic bite block

Conditions: Gastric Disease

Summary: this study will test a novel endoscopic bite block during upper endoscopy.

this study will feasibility and comfort of the novel endoscopic bite block that contains a compressible addition to the traditional endoscopic bite block offering cushioning for the teeth and the ability to resist mispositioning when a patient opens their mouth (ie, during a yawn).

Eligibility criteria:
inclusion criteria 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, \> 18 years of age 4. deemed appropriate for scheduled upper endoscopy by endoscopy and anesthesia staff exclusion criteria: 1. known allergic reactions to components of the novel endoscopic bite block
biospecimen analysis in determining effects of chemotherapy on fertility in osteosarcoma survivors

Conditions: Osteosarcoma

Summary: this research trial studies saliva, semen, and blood samples to determine effects of chemotherapy on fertility in osteosarcoma survivors. study biospecimen samples from osteosarcoma survivors in the laboratory may help doctors learn whether chemotherapy causes fertility problems and to learn more about the long term effects.

primary objectives: i. determine whether infertility and/or biomarkers of spermatogenesis and steroidogenesis differ in male osteosarcoma survivors treated with cisplatin with or without ifosfamide compared to male controls without a history of cancer. ii. evaluate whether cisplatin with or without ifosfamide for the treatment of osteosarcoma alters sperm deoxyribonucleic acid (dna) methylation. exploratory objectives: i. evaluate the role of genetic susceptibility in the development of impairments in spermatogenesis or steroidogenesis with contemporary regimens for the treatment of osteosarcoma. outline: participants complete a health questionnaire over 30-45 minutes. patients also provide saliva and semen samples and undergo collection of blood.

Eligibility criteria:
inclusion criteria: * received upfront therapies for osteosarcoma, which included cisplatin, (with or without other agents) * patient must have completed cancer treatment \>= 2 years prior to study enrollment * osteosarcoma survivors without a systemically treated relapse or subsequent malignancy * note: history of relapse or second malignancy is permitted if treated with local therapy only (e.g. surgery, radiation) * able to speak, read and write in english, french or spanish * all patients and/or their parents or legal guardians must sign a written informed consent * all institutional, food and drug administration (fda), and national cancer institute (nci) requirements for human studies must be met
cognitive reappraisal in adolescents with major depression

Conditions: Major Depressive Disorder

Summary: major depression (md) is common during adolescence and associated with significant morbidity and mortality. one important factor for the development and maintenance of adolescent md are disturbances in emotion regulation, including deficits in cognitive reappraisal (cr). cr is a particularly effective emotion regulation strategy that aims at reinterpreting emotional events to modify affective responses. adolescents with md apply this strategy less often than their healthy peers and show disturbances in brain activation patterns underlying cr. in this study, md adolescents will be randomly assigned to a group that receives a task-based training in cr or to a control training group. it will be examined whether the task-based cr training is superior to the control training with regard to improvements in negative affect, perceived stress in daily life and depressive symptoms. moreover, during the four training sessions, the event-related potential "late positive potential" (lpp) will be recorded to assess neurophysiological indices of cr processes and gaze fixations on emotional areas within negative pictures and affective responses to pictures will be collected to identify mechanisms underlying training effects.this study will provide first evidence for the efficacy of a short-time training that has previously shown to be effective in healthy individuals. moreover, the study will identify neurobiological mechanisms that predict training effects. the results of this investigation will lay the ground for a clinical trial to investigate whether a cr training added to an established intervention improves treatment effects for adolescent md.


Eligibility criteria:
inclusion criteria: * female and male participants * age range: 12-18 years * current diagnosis of md (icd-10 diagnoses f32.0; f32.1; f32.2, f33.0, f33.1, f.33.2) * intelligence quotient (iq) of ≥ 80 exclusion criteria: * neurological disorders * schizophrenic disorder * pervasive developmental disorder * bipolar disorder * borderline personality disorder * substance dependence disorder * gender dysphoria. participants comorbid with psychiatric comorbidities other than those listed above are included if md is the primary diagnosis.

Keywords: emotion regulation training lpp adolescence major depression eye-tracking cognitive reappraisal event-related potentials
18f-fluoromisonidazole and fludeoxyglucose f 18 pet/ct patients with soft tissue sarcoma

Conditions: Recurrent Adult Soft Tissue Sarcoma; Stage I Adult Soft Tissue Sarcoma; Stage II Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma

Summary: this phase ii trial is studying 18f-fluoromisonidazole and fludeoxyglucose f 18 pet/ct scans to see how well they work in assessing oxygen in tumor tissue of patients with soft tissue sarcoma undergoing chemotherapy with or without radiation therapy. using diagnostic procedures, such as 18f-fluoromisonidazole and fludeoxyglucose f 18 pet scan and ct scan, to find oxygen in tumor cells may help in planning cancer treatment. it may also help doctors predict how well a patient will respond to treatment.

primary objectives: i. evaluate the potential of 18f-fluoromisonidazole (\[18f\] fmiso) as a non-invasive indicator of tissue hypoxia to provide tumor-imaging data that correlates with tissue markers of hypoxia in patients with soft tissue sarcoma treated with neoadjuvant chemotherapy with or without radiotherapy. secondary objectives: i. test \[18f\] fmiso tumor uptake as an independent predictor of patient outcome and if it provides additional predictive power over fludeoxyglucose f 18 pet scan. ii. test \[18f\] fmiso tumor uptake as a predictor of response in the subgroup of patients treated with radiotherapy and chemotherapy. iii. test the reproducibility of \[18f\] fmiso uptake in tumors by imaging the same patients on sequential days in a test-retest protocol. iv. determine the relationship between hypoxia-related biomarkers (hif1-a and vegf), proliferation biomarkers (microvascular density, p53, and ki-67), and regional \[18f\] fmiso uptake in tumor. outline: patients undergo fludeoxyglucose f 18 \[18f\] fdg and 18f-fluoromisonidazole (\[18f\] fmiso) positron emission tomography (pet)/ct scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy. note: some patients may undergo repeat \[18f\] fmiso pet/ct scan within 48 hours after the first \[18f\] fmiso scan to evaluate the variability (test-retest) of this imaging measurement. blood samples are collected after completion of \[18f\] fmiso and \[18f\] fdg pet/ct scans for laboratory biomarker studies by ihc assays. tumor samples from biopsy or surgery are also collected for biomarker studies. after completion of study procedures, patients are followed up periodically for 2 years.

Eligibility criteria:
inclusion criteria: * histologically confirmed intermediate- or high-grade soft tissue sarcoma * biopsy proven or highly suspicious primary or recurrent disease * tumor size ≥ 2 cm * scheduled to undergo neoadjuvant chemotherapy with or without radiotherapy * life expectancy ≥ 12 months * negative pregnancy test * willing to undergo pet scanning * willing to undergo possible urinary bladder catheterization (for patients with pelvic or proximal thigh tumors) * able to lie on the imaging table for up to 1.5 hours * weight ≤ 400 lbs * not pregnant
impact of estocma on ocd family members

Conditions: Obsessive-Compulsive Disorder (OCD)

Summary: the goal of this clinical trial is to test the acceptability, feasibility, and effectiveness of estocma in families and relatives of individuals with obsessive-compulsive disorder (ocd). specifically, a randomized controlled trial with two conditions (experimental and control) has been carried out in a sample of families and relatives of individuals with obsessive-compulsive disorder to assess pre-post-intervention changes. researchers will compare experimental and control group to see if after using the app there is: lower stigma, higher knowledge and understanding about ocd, higher intention to seek help, and higher self-esteem and lower obsessive-compulsive symptoms. and there are no changes in the control group. the experimental group received the intervention through the estocma app.


Eligibility criteria:
inclusion criteria: * having signed the informed consent * being over 18 years of age; * having an android or ios mobile device with internet access * being a family member of a person diagnosed with ocd. exclusion criteria: * not completing one or more of the evaluation time points (pre- or post-intervention) * not finishing the intervention (experimental group only)

Keywords: stigma obsessive-compulsive disorder family mental health literacy estocma app
ambulatory alcohol detoxification with remote monitoring

Conditions: Alcohol Use Disorder

Summary: this study is designed to examine the feasibility and impact of the use of remote monitoring devices during an outpatient ambulatory alcohol detoxification treatment for patients with alcohol use disorders.

the study will include 30 subjects with a diagnosis of alcohol use disorder. the study uses a breathalyzer device with facial recognition to confirm the patient's identity and sends the information to the study staff using cellular technology. a second device is used which is a wireless blood pressure cuff that connects to the patient's smartphone and sends blood pressure and heart rate measurements directly to the study physician for enhanced monitoring during alcohol withdrawal management. the duration of the study is 8 days, starting with an initial appointment to set up the equipment. throughout the study, surveys are completed by subjects in regards to their experience with the device. subjects undergo a brief 30-60 minute appointment on the first day of the study, appointments as needed throughout the study, and an appointment on the last day of the study to check in with the physician for ongoing ambulatory management of alcohol withdrawal, including medication adjustments if indicated.

Eligibility criteria:
inclusion criteria: * male or female subject between the ages of 21-75 years old * meeting dsm-v criteria for alcohol use disorder and needing medically supervised detoxification based on medical history and pattern of alcohol use delineated by timeline follow back method. * has 24/7 easy access to a hospital. this is to ensure easy admission to a higher level of care if indicated. * willing to use the soberlink device to provide blood alcohol concentration (bac) * willing to use the blood pressure cuff to provide blood pressure and pulse (bppt) measurement * willing to sign an informed consent exclusion criteria: * bac above the legal driving limit at the time of screening * developing symptoms or history of symptoms of severe withdrawal syndrome such as fever, disorientation, drenching sweats, severe tachycardia, or severe hypertension * history of delirium tremens or seizures * co-morbid medical or psychiatric history requiring inpatient admission for careful monitoring * subject unwilling to respond to redirection when blood pressure and heart rate warning signs are triggered * does not have an iphone, ipod, ipad, or apple watch with ios 7.0 or later, or does not have an android phone or tablet with android 4.4 or later * unable or unwilling to properly use the monitoring devices, or find the monitoring devices an obstruction to comply with treatment * subject that is non-english speaking * subject that is a child, adolescent, or cognitively impaired

Keywords: ambulatory alcohol detoxification alcohol withdrawal remote monitoring with breathalyzer
effects of bilateral gpi dbs on freezing of gait in pd

Conditions: Parkinson Disease

Summary: this study aims to evaluate the effect of deep brain stimulation in the the globus pallidus (gpi) on freezing of gait in patients with parkinson's disease.


Eligibility criteria:
inclusion criteria: (1) idiopathic pd, according to the mds parkinson's disease society diagnostic criteria17; (2) bilateral gpi-dbs implant according to a careful consideration of patients' symptom profiles (e.g., existence and severity of dyskinesia, dystonia, axial symptoms, or cognitive and mood problems); (3) onset of pd at or before 70 years of age; and (4) disease duration of more than 3 years at the time of surgery. patients were excluded if they had unstable vital signs or medical and psychiatric comorbidities at the time of the study.

Keywords: freezing of gait parkinson disease gpi
effect of montelukast on basophils, in-vitro

Conditions: Allergic Asthma; Allergic Rhinitis

Summary: subjects with either allergic asthma or allergic rhinitis will be recruited to obtain blood. this blood will be used to be stimulated with to whatever the patient allergic. in the laboratory, this stimulated blood will be measured for histamine, leukotrienes, il-13 and il-3. these are chemicals responsible for allergy symptoms.


Eligibility criteria:
inclusion criteria: * allergic asthma or allergic rhinitis * age 12+ exclusion criteria: * smokers

Keywords: il13 leukotriene histamine il4 must be allergic asthma or allergic rhinitis
drug-coated balloon in combination with new generation drug-eluting stent in the treatment of long diffuse coronary artery disease

Conditions: Coronary Artery Disease

Summary: an observational study to evaluate safety and efficacy of the hybrid approach des/dcb in the treatment of long diffuse de novo coronary artery disease

this is a prospective, non-randomized, single-arm, multi-center study aiming to assess the feasibility and the clinical outcomes of using the restore dcb (cardionovum gmbh, bonn, germany) in combination ("hybrid approach") with a new generation des (type at operator's discretion) for the treatment of diffuse cad (coronary artery disease) encountered in daily clinical practice (lesion length \> 38 mm). the rationale of the proposed strategy derives from the characteristics of dcb in treating the atherosclerotic disease without leaving a permanent structure in the vessel especially in case of diffuse cad -avoiding a long metallic, permanent cage within extended coronary segments

Eligibility criteria:
inclusion criteria: * patients presenting with stable or unstable cad eligible for pci (according to the international guidelines) because of diffuse long (\>38 mm) cad involving contiguous segments of the same vessel suitable for a hybrid approach (rvd\>2.75 mm in the proximal des target segment and rvd ≤2.75 mm ≥ 2.0 mm for the distal dcb target segment); * signed patient informed consent/data release form exclusion criteria: * age \<18 years; * cardiogenic shock; * pregnancy or breastfeeding; * target vessel reference diameter (within planned device deployment segments) \ 5.0 mm; * comorbidities with life expectancy \<12 months * severe calcification or/tortuosity proximally or at the dcb target segment; * prior pci and stent implantation in the target vessel.
rehabilitation and exercise training after hospitalization

Conditions: Heart Failure

Summary: rehabilitation and exercise training after hospitalization: assessing benefit in acute heart failure (rehab-hf) pilot is a multi-site, randomized clinical pilot study designed to establish the feasibility of conducting a larger clinical trial to address the hypothesis that, in addition to standard care, a novel, progressive, multi-domain 3-month rehabilitation intervention administered to elderly patients with acute decompensated heart failure (adhf) will improve key clinical outcomes, including the rate of rehospitalization and death, physical function, and quality of life.

three centers,wake forest baptist health along with thomas jefferson university hospital-co-investigator dr. david whellan, and duke medical center- co-investigator dr. christopher o'connor, will recruit a total of 60 consenting patients ≥ 60 years old hospitalized with adhf. once identified and screened, the participants will be randomized in a 1:1 fashion to receive a 3 month novel rehabilitation and exercise training intervention or usual care. this multi-domain intervention will include endurance, mobility, strength, and balance training and be tailored based on participant performance in each of these domains. it will begin during the hospitalization and continue three times per week in an outpatient facility.

Eligibility criteria:
inclusion criteria: * age ≥ 60 years old * hospitalized for the management of adhf or diagnosed with adhf after being hospitalized for another reason. adhf will be defined as a combination of symptoms, signs, and hf-specific medical treatments. exclusion criteria: * planned discharge other than to home or a facility where the participant will live independently. * acute myocardial infarction * already participating in cardiac rehabilitation

Keywords: heart failure
an exercise intervention for prostate cancer patients receiving androgen deprivation therapy

Conditions: Prostate Cancer; Physical Activity; Side-effects

Summary: this main purpose of this study is to examine the effects of an exercise intervention to counteract adverse side effects related to androgen deprivation therapy (adt) in prostate cancer patients. specifically, a supervised and home-based exercise program will be used to assess its impact on clinical and behavioral variables related to adt in prostate cancer patients.

this study will assess the feasibility of an exercise intervention to counteract adverse side effects related to adt in prostate cancer (pca) patients. specifically, we will use an exercise intervention and assess its impact on bone mass density, body mass index (bmi), hip/waist circumference levels, biomarkers (i.e., glucose, lipids), step count, grip strength, and health-related quality of life (hrqol) using the patient reported outcomes measurement information system (promis®). in this 8-week two-arm randomized clinical trial, 40 pca patients receiving adt will be randomly assigned to an exercise (n=20) or a stretching control group (n=20) with a follow-up at 8-weeks.

Eligibility criteria:
inclusion criteria: * (1) caucasian or african-american/black men; (2) histologically confirmed non-metastatic pca; (3) receiving adt treatment for 9-months or less upon recruitment (and continue to receive treatment during the duration of the study); (4) 40 to 75 years old; (5) sedentary defined as \<60 minutes of recreation or work requiring modest pa/week; (6) ability to perform the level of physical activity assessed by the physical activity readiness questionnaire (par-q); (6) has access to a smartphone or computer with internet capabilities exclusion criteria: * (1) severe cardiac disease; (2) recent myocardial infarction; (3) treated for any other cancer; (4) any physical, psychological illness, and/or medical problems that restricted them from exercise; (5) and not willing or able to follow procedures specified by the study and/or instructions of the researcher.

Keywords: prostate cancer physical activity exercise intervention side effects androgen deprivation therapy